Target intelligence / Profile preview

Perforin and granzyme pathway

Molecular classification
Pathway, Enzyme (granzymes), Pore-forming protein (perforin)
01

Overview

The Perforin and granzyme pathway is a central mechanism by which cytotoxic lymphocytes—such as cytotoxic T cells and natural killer cells—induce apoptosis in virus-infected cells and tumor cells. The process involves two main components: perforin, a pore-forming protein that creates channels in the target cell membrane; and granzymes, a family of serine proteases that enter the target cell through these pores. Once inside the target cell cytoplasm, granzymes cleave specific substrates to trigger programmed cell death pathways such as caspase activation. This highly specific killing mechanism ensures minimal damage to surrounding healthy tissues while efficiently eliminating abnormal cells. Recent research has also highlighted alternative mechanisms for granzyme entry into target cells via receptor-mediated endocytosis independent of perforin pores. The canonical model remains that perforin facilitates efficient delivery of granzymes into the cytosol where they execute their apoptotic functions. The Perforin and granzyme pathway is essential for immune defense against viral infections and cancer but can also contribute to pathological conditions like graft-versus-host disease when dysregulated.

Other names
Granule exocytosis pathwayCytotoxic lymphocyte-mediated apoptosis pathwayPerforin/granzyme-dependent cell death pathway
02

Mechanism of action

Inhibition of perforin or granzymes to block cytotoxic lymphocyte-mediated apoptosis; potential use as immunosuppressants in transplantation or autoimmunity

03

Biological functions

ApoptosisCell deathImmune responseCytotoxicity
04

Disease associations

Cancer (immune surveillance of tumors)Infection (viral clearance)Graft-versus-host disease (GvHD)Autoimmunity
05

Safety considerations

Potential impairment of immune surveillance leading to increased risk of infections or tumor development if inhibited long-term.However, short-term inhibition may not affect basal hematopoiesis or progenitor cell engraftment post-transplant according to some studies.Risk assessment is ongoing.
06

Interacting drugs

No FDA-approved drugs specifically targeting this pathway; investigational inhibitors of perforin or granzymes are under study for GvHD and autoimmune diseases
07

Biomarkers

Perforin expression levelsGranzyme B activity/levels in serum or tissue biopsies; used as markers of cytotoxic T cell activity in immune monitoring and disease states such as GvHD

Beyond the preview

Go deeper on Perforin and granzyme pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perforin and granzyme pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call